HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation

Nature

Volumn 526, Issue 7572, 2015, Pages 212-217

  Rosa, Annachiara ^a   Chande, Ajit ^a   Ziglio, Serena ^a   De Sanctis, Veronica ^a   Bertorelli, Roberto ^a   Goh, Shih Lin ^b   McCauley, Sean M ^b   Nowosielska, Anetta ^b   Antonarakis, Stylianos E ^c,d   Luban, Jeremy ^b   Santoni, Federico Andrea ^c   Pizzato, Massimo ^a  

^a UNIVERSITY OF TRENTO   (Italy)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d Institute of Genetics and Genomics of Geneva (iGE3)   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; NEF PROTEIN; RAB7 PROTEIN; SERINC3; SERINC5; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN; RAB PROTEIN; SERINC3 PROTEIN, HUMAN; SERINC5 PROTEIN, HUMAN; TUMOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD; CANCER; CELLS AND CELL COMPONENTS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; INFECTIVITY; INHIBITION; MEMBRANE; PLASMA; PRIMATE; PROTEIN;

ARTICLE; CONTROLLED STUDY; ENDOSOME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; VIRION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL MEMBRANE; CHEMISTRY; HOST PATHOGEN INTERACTION; HOST RANGE; METABOLISM; MOLECULAR EVOLUTION; PHYSIOLOGY; PRIMATE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; PRIMATE LENTIVIRUS GROUP;

ANIMALS; CELL LINE; CELL MEMBRANE; ENDOSOMES; EVOLUTION, MOLECULAR; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; HIV-1; HOST SPECIFICITY; HOST-PATHOGEN INTERACTIONS; HUMANS; LEUKEMIA VIRUS, MURINE; MEMBRANE PROTEINS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; NEOPLASM PROTEINS; PRIMATES; RAB GTP-BINDING PROTEINS; RECEPTORS, CELL SURFACE; VIRION;

EID: 84944049517     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature15399     Document Type: Article

References (50)

1. Kestler, H. W. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651-662 (1991).
2. Deacon,N. J. et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988-991 (1995).
3. Kirchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, J. L. & Desrosiers, R. C. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332, 228-232 (1995).
4. Landi, A., Iannucci, V., Nuffel, A. V., Meuwissen, P. & Verhasselt, B. One protein to rule them all:modulation of cell surface receptors and molecules by HIV Nef. Curr. HIV Res. 9, 496-504 (2011).
5. Baur, A.S. et al. HIV-1Nef leads to inhibition or activation ofT cells depending onits intracellular localization. Immunity 1, 373-384 (1994).
6. Schrager, J. A. & Marsh, J. W. HIV-1 Nef increases T cell activation in a stimulusdependent manner. Proc. Natl Acad. Sci. USA 96, 8167-8172 (1999).
7. Alexander, L., Du, Z., Rosenzweig, M., Jung, J. U.& Desrosiers, R. C. A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. J. Virol. 71, 6094-6099 (1997).
8. Simmons, A., Aluvihare, V. & McMichael, A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14, 763-777 (2001).
9. Stolp, B. et al. HIV-1 Nef interferes with host cellmotility by deregulation of Cofilin. Cell Host Microbe 6, 174-186 (2009).
10. Chowers, M. Y. et al. Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J. Virol. 68, 2906-2914 (1994).
11. Munch, J. et al. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J. Virol. 81, 13852-13864 (2007).
12. Carl, S. et al. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J. Virol. 75, 3657-3665 (2001).
13. Aiken,C.& Trono, D.Nef stimulateshuman immunodeficiency virus type1proviral DNA synthesis. J. Virol. 69, 5048-5056 (1995).
14. Chowers, M. Y., Pandori, M. W., Spina, C. A., Richman, D. D. & Guatelli, J. C. The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 212, 451-457 (1995).
15. Schwartz, O., Marechal, V., Danos, O. & Heard, J. M. Human immunodeficiency virus type1 Nef increases the efficiency of reverse transcription in the infected cell. J. Virol. 69, 4053-4059 (1995).
16. Pizzato,M.MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. Proc. Natl Acad. Sci. USA 107, 9364-9369 (2010).
17. Usami, Y., Popov, S.& Gottlinger, H. G. The Nef-Like effect ofmurine leukemia virus glycosylated Gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex. J. Virol. 88, 3443-3454 (2014).
18. Grossman, T. R., Luque, J. M. & Nelson, N. Identification of a ubiquitous family of membrane proteins and their expression in mouse brain. J. Exp. Biol. 203, 447-457 (2000).
19. Xu, J. et al. Cloning and expression of a novel human C5orf12 gene, a member of the TMS-TDE family. Mol. Biol. Rep. 30, 47-52 (2003).
20. Inuzuka, M., Hayakawa, M. & Ingi, T. Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis. J. Biol. Chem. 280, 35776-35783 (2005).
21. Craig, H.M., Pandori, M. W.& Guatelli, J. C. Interaction ofHIV-1 Nef with the cellular dileucine-based sorting pathway is required forCD4down-regulation and optimal viral infectivity. Proc. Natl Acad. Sci. USA 95, 11229-11234 (1998).
22. Pizzato,M. et al. Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc. Natl Acad. Sci. USA 104, 6812-6817 (2007).
23. Saksela, K., Cheng, G. & Baltimore, D. Proline-rich (PxxP)motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef1 viruses but not for down-regulation of CD4. EMBO J. 14, 484-491 (1995).
24. Piguet, V. et al. Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of b-COP in endosomes. Cell 97, 63-73 (1999).
25. Miller, M. D., Warmerdam, M. T., Page, K. A., Feinberg, M. B. & Greene, W. C. Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J. Virol. 69, 579-584 (1995).
26. Aiken, C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71, 5871-5877 (1997).
27. Chazal, N., Singer, G., Aiken, C., Hammarskjold, M. L. & Rekosh, D. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pHno longer require Nef for optimal infectivity. J. Virol. 75, 4014-4018 (2001).
28. Pizzato, M., Popova, E. & Gottlinger, H. G. Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles. J. Virol. 82, 10811-10819 (2008).
29. Luo, T.,Douglas, J. L., Livingston,R. L.&Garcia, J.V. Infectivity enhancement byHIV- 1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology 241, 224-233 (1998).
30. Lai, R. P. et al. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog. 7, e1002442 (2011).
31. Usami, Y. & Gottlinger, H. HIV-1 Nef responsiveness is determined by env variable regions involvedintrimer associationandcorrelates withneutralizationsensitivity. Cell Rep. 5, 802-812 (2013).
32. Campbell, E. M., Nunez, R. & Hope, T. J. Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. J. Virol. 78, 5745-5755 (2004).
33. Schaeffer, E.,Geleziunas,R.& Greene,W.C.Human immunodeficiency virus type1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J. Virol. 75, 2993-3000 (2001).
34. Zhou, J.& Aiken,C. Nefenhanceshumanimmunodeficiency virus type1infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope. J. Virol. 75, 5851-5859 (2001).
35. Tobiume,M., Lineberger, J. E., Lundquist, C. A.,Miller, M. D.& Aiken, C. Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J. Virol. 77, 10645-10650 (2003).
36. Cavrois, M., Neidleman, J., Yonemoto, W., Fenard, D. & Greene, W. C. HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology 328, 36-44 (2004).
37. Day, J.R.,Munk, C.& Guatelli, J. C. Themembrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity. J. Virol. 78, 1069-1079 (2004).
38. Cavrois,M., De Noronha, C.& Greene, W. C. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nature Biotechnol. 20, 1151-1154 (2002).
39. van der Aa, L. M. et al. A large new subset of TRIM genes highly diversified by duplication and positive selection in teleost fish. BMC Biol. 7, 7 (2009).
40. Duggal, N. K.& Emerman,M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nature Rev. Immunol. 12, 687-695 (2012).
41. Briggs, J. A., Wilk, T., Welker, R., Kräusslich, H. G. & Fuller, S. D. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22, 1707-1715 (2003).
42. Cohen, F. S. & Melikyan, G. B. The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement. J. Membr. Biol. 199, 1-14 (2004).
43. Razinkov, V. I.& Cohen, F. S. Sterols and sphingolipids strongly affect the growth of fusion pores induced by the hemagglutinin of influenza virus. Biochemistry 39, 13462-13468 (2000).
44. Ciechonska, M. & Duncan, R. Lysophosphatidylcholine reversibly arrests pore expansion during syncytiumformationmediated by diverse viral fusogens. J. Virol. 88, 6528-6531 (2014).
45. Chen, A. et al. Fusion-pore expansion during syncytium formation is restricted by an actin network. J. Cell Sci. 121, 3619-3628 (2008).
46. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnol. 15, 871-875 (1997).
47. Pizzato, M. et al. A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses incell culture supernatants. J. Virol. Methods 156, 1-7 (2009).
48. Simon, J. H., Gaddis, N. C., Fouchier, R. A. & Malim, M. H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nature Med. 4, 1397-1400 (1998).
49. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
50. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifyingmammalian transcriptomes byRNA-Seq. NatureMethods 5, 621-628 (2008).